GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lannett Co Inc (OTCPK:LCINQ) » Definitions » Forward PE Ratio

Lannett Co (Lannett Co) Forward PE Ratio : 0.00 (As of Apr. 25, 2024)


View and export this data going back to 1994. Start your Free Trial

What is Lannett Co Forward PE Ratio?

Lannett Co's Forward PE Ratio for today is 0.00.

Lannett Co's PE Ratio without NRI for today is 0.00.

Lannett Co's PE Ratio for today is 0.00.


Lannett Co Forward PE Ratio Historical Data

The historical data trend for Lannett Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lannett Co Forward PE Ratio Chart

Lannett Co Annual Data
Trend 2015-12 2016-12 2017-12 2018-12 2019-12 2020-12 2021-06
Forward PE Ratio
9.35 6.40 7.76 2.52 7.91 13.04 13.14

Lannett Co Quarterly Data
2015-12 2016-03 2016-06 2016-09 2016-12 2017-03 2017-06 2017-09 2017-12 2018-03 2018-06 2018-09 2018-12 2019-03 2019-06 2019-09 2019-12 2020-03 2020-06 2020-09 2020-12 2021-03
Forward PE Ratio 9.35 5.00 6.77 7.22 6.40 7.14 7.34 7.18 7.76 5.84 5.89 2.27 2.52 7.87 5.77 10.16 7.91 5.18 5.71 9.77 13.04 16.64

Competitive Comparison of Lannett Co's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Lannett Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lannett Co's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lannett Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Lannett Co's Forward PE Ratio falls into.



Lannett Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Lannett Co  (OTCPK:LCINQ) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Lannett Co Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Lannett Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lannett Co (Lannett Co) Business Description

Traded in Other Exchanges
N/A
Address
1150 Northbrook Drive, Suite 155, Trevose, PA, USA, 19053
Lannett Co Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products. It offers solid oral, extended-release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. In addition, the company also provides its products for various medical indications comprising glaucoma, gastrointestinal, migraine, obesity, respiratory, and others. It operates in the segment of generic pharmaceuticals. Its customers include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, and others.
Executives
John C Chapman director 9000 STATE ROAD, PHILADELPHIA PA 19136
Timothy C Crew officer: Chief Executive Officer 9000 STATE ROAD, PHILADELPHIA PA 19136
Patrick G Lepore director 17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Melissa Rewolinski director 9000 STATE ROAD, PHILADELPHIA PA 19136
Jeffrey Farber officer: Secretary
Samuel H Israel officer: Chief Legal Officer 9000 STATE ROAD, PHILADELPHIA PA 19136
John Abt officer: Vice President of Quality 9000 STATE ROAD, PHILADELPHIA PA 19136
John Kozlowski officer: Chief Operating Officer 9000 STATE ROAD, PHILADELPHIA PA 19136
David A Drabik director 9000 STATE RD, PHILADELPHIA PA 19136
Paul Taveira director 9000 STATE ROAD, PHILADELPHIA PA 19136
Albert Iii Paonessa director 9852 NW 2ND COURT, PLANTATION FL 33324
Kevin Smith other: Vice President
Maureen Cavanaugh officer: Senior Vice President and CCOO 9000 STATE ROAD, PHILADELPHIA PA 19136
David Farber officer: Treasurer
Arthur P Bedrosian officer: President P O BOX D 1400, POMONA NY 10970